Loading...
We would love for you to become a part of our community. Join our Discord to connect with us and other members!
- Ticker
- ACET
- Price
- 0.91
- Stock movement down
- -0.01 (-1.28%)
- Company name
- Adicet Bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 74.98M
- Ent value
- 3.93M
- Price/Sales
- 5.82
- Price/Book
- 0.35
- Div yield
- 4.40%
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -62.08%
- 3 year return
- -58.45%
- 5 year return
- -38.52%
- 10 year return
- -
Last updated: 2025-01-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ACET does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.82 |
| Price to Book | 0.35 |
| EV to Sales | 0.31 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 82.40M |
| EPS (TTM) | -1.30 |
| FCF per share (TTM) | -1.02 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 12.89M |
| Gross profit (TTM) | 7.95M |
| Operating income (TTM) | -128.44M |
| Net income (TTM) | -117.88M |
| EPS (TTM) | -1.30 |
| EPS (1y forward) | -1.30 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 61.67% |
| Operating margin (TTM) | -996.11% |
| Profit margin (TTM) | -914.25% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 105.48M |
| Net receivables | 210.00K |
| Total current assets | 206.32M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 58.83M |
| Total assets | 245.96M |
| Accounts payable | 2.50M |
| Short/Current long term debt | 18.20M |
| Total current liabilities | 19.39M |
| Total liabilities | 34.43M |
| Shareholder's equity | 211.53M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -91.76M |
| Capital expenditures (TTM) | 1.08M |
| Free cash flow (TTM) | -92.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -55.73% |
| Return on Assets | -47.93% |
| Return on Invested Capital | -54.88% |
| Cash Return on Invested Capital | -43.22% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.91 |
| Daily high | 0.95 |
| Daily low | 0.90 |
| Daily Volume | 90K |
| All-time high | 145.95 |
| 1y analyst estimate | 6.40 |
| Beta | 1.70 |
| EPS (TTM) | -1.30 |
| Dividend per share | 0.04 |
| Ex-div date | 21 Sep 2018 |
| Next earnings date | 17 Mar 2025 |
Downside potential
Loading...
Downside potential data
| ACET | S&P500 | |
| Current price drop from All-time high | -99.38% | -1.70% |
| Highest price drop | -99.42% | -56.47% |
| Date of highest drop | 19 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -82.49% | -11.11% |
| Avg time to new high | 196 days | 12 days |
| Max time to new high | 1741 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
74.98M
Marketcap category
Small-cap
Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Employees
143
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page